tirzepatide cardiovascular outcomes trial results july 2025 60-Second Journal Club: The SUMMIT examined of treatment with in patients with heart failure with preserved ejection fraction and obesity. Read the full trial Bridging the gap between GLP1-receptor

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity About the Author Craig Primack, MD, FACP, MFOMA is the Founder and Managing Member of Scottsdale Weight Loss Center and a leading physician in medical weight loss

While the video does not provide medical advice, it gives visual learners a clearer sense of how KLOW fits into a busy lab environment and reinforces the research-only status of the product

This risk is most pronounced during dose escalation and following dose increases, when gastrointestinal effects are typically strongest

Diabetes Medications and the Risk of Hypoglycemia If you are taking tirzepatide for weight loss but also have type 2 diabetes, you may already be using other glucose-lowering drugs